BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress March 6, 2026
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates February 27, 2026
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs January 9, 2026
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium December 12, 2025
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS) November 3, 2025
